Leerink Partnrs Issues Optimistic Estimate for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Research analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for ACADIA Pharmaceuticals in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of $0.10 for the quarter, up from their previous estimate of $0.04. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' FY2025 earnings at $0.65 EPS and FY2029 earnings at $2.10 EPS.

Several other equities analysts also recently weighed in on ACAD. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Morgan Stanley restated an "equal weight" rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Guggenheim downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "hold" rating and a $22.00 target price for the company. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.93.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD stock traded down $0.23 on Wednesday, reaching $14.50. 409,329 shares of the company were exchanged, compared to its average volume of 1,845,622. The company has a market cap of $2.42 billion, a price-to-earnings ratio of 18.59 and a beta of 0.54. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $20.68. The business has a 50-day moving average price of $17.16 and a 200 day moving average price of $16.95.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of ACADIA Pharmaceuticals by 3.0% in the 3rd quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company's stock valued at $91,878,000 after purchasing an additional 173,084 shares in the last quarter. Barclays PLC lifted its holdings in ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after buying an additional 154,854 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company's stock worth $44,234,000 after acquiring an additional 30,826 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of ACADIA Pharmaceuticals by 67.8% in the 3rd quarter. Principal Financial Group Inc. now owns 129,551 shares of the biopharmaceutical company's stock valued at $1,992,000 after acquiring an additional 52,340 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in ACADIA Pharmaceuticals by 1.3% during the fourth quarter. Nordea Investment Management AB now owns 264,031 shares of the biopharmaceutical company's stock worth $4,952,000 after purchasing an additional 3,516 shares during the last quarter. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total value of $54,065.55. Following the completion of the transaction, the executive vice president now owns 56,889 shares in the company, valued at approximately $969,957.45. This trade represents a 5.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at $320,756.85. The trade was a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,169 shares of company stock worth $242,686. Corporate insiders own 28.30% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.